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KESAN IN VIVO SIROLIMUS DAN SUNITINIB PADA PENANDA 
PROGNOSTIK KANSER PAYUDARA 
ABSTRAK 
Kanser payu dara merupakan penyakit heterogen yang mempunyai 
kepelbagaian ciri-ciri klinikal, patologikal, dan molekul. Kanser payu dara 
merupakan kanser yang paling banyak didiagnos dalam kalangan wanita, dan 
merupakan punca utama kematian wanita di seluruh dunia.  Reseptor hormon seperti 
Estrogen Receptor (ER), Progesterone Receptor (PgR) dan Human Epidermal 
Growth Factor Receptor-2 (HER2/neu) adalah penanda rutin dalam prognosis kanser 
payu dara, dan membantu dalam menentukan jenis perawatan yang terbaik. 
Sirolimus, merupakan sejenis ubat semulajadi mikrolid daripada bakteria yang 
mampu  menyekat imuniti dan menghalang percambahan sel kanser dengan cara 
menghalang pengaktifan mTOR. Sunitinib pula merupakan perencat tyrosine kinase 
yang bersifat menghalang proses angiogenesis. Oleh itu, ianya menarik untuk 
mengkaji kesan Sirolimus dan Sunitinib dalam menghalang perkembangan kanser 
payu dara daripada aruhan hormon. Dalam kajian ini, kanser payu dara diaruh 
dengan menggunakan N-Nitroso-N-Methylurea (NMU) dengan dos 70mg/ kg berat 
badan terhadap 32 ekor tikus betina strain Sparague Dawley. Pengekspresan gen dan 
protein untuk ketiga-tiga reseptor ini ditentukan dengan mengggunakan teknik   
imunohistokimia dan Real-Time PCR.   Hasilnya, semua tumor payu dara merupakan 
100% malignan, mempunyai ciri invasive breast carcinoma (IBC) yang 
kebanyakannya adalah jenis cribriform, papillary dan no special type (NST). 
Perawatan dengan Sirolimus menunjukkan penyekatan perkembangan tumor dan 
mengurangkan pengekspresan protein ER dan PgR. Walaubagaimanapun, berlaku 
xviii 
peningkatan ekspresi pada tahap gen mungkin disebabkan Sirolimus menggalakkan 
regulasi pos-transkripsi berlaku. Manakala, perawatan dengan Sunitinib merencat 
perkembangan tumor selepas rawatan pertama, tetapi berlaku peningkatan diameter 
tumor selepas rawatan kedua. Perawatan dengan Sunitinib juga tidak menunjukkan 
pengurangan pengkspresan yang signifikan bagi ER dan PgR. Walaubagaimanapun, 
dari sudut histologi, perawatan dengan Sunitinib tidak menghasilkan sebarang jenis 
ductal NST yang agresif. Dalam kajian ini, semua kanser payu dara diaruh dengan NMU 
menunjukkan skor negative pengekspresan HER2/neu.  Perawatan kombinasi 
menyebabkan tumor berjaya direncat, dan ianya dijangka disebabkan oleh Sirolimus 
lebih menunjukkan kesan antikanser berbanding Sunitinib. Oleh itu, kajian ini 




IN VIVO EFFECTS OF SIROLIMUS AND SUNITINIB ON BREAST 
CANCER PROGNOSTIC MARKERS 
ABSTRACT 
Breast cancer is a heterogeneous disease with a wide variety of clinical, 
pathological, and molecular characteristics, the most commonly diagnosed cancer 
among females and the leading cause of women cancer death. Hormone receptor 
studies such as estrogen receptor (ER), progesterone receptor (PgR), and human 
epidermal growth factor receptor-2 (HER2/neu) are routinely done in prognosis of 
breast carcinoma and helps in deciding the best treatment. Sirolimus is a natural 
macrocyclic lactone drug from bacteria with immunosuppressive and anti-
proliferative properties by inhibiting mechanistic target of rapamycin (mTOR). 
Sunitinib is a tyrosine kinase inhibitor (TKI) with antiangiogenic properties. 
Therefore, it will be interesting to analyse the effect of Sirolimus and Sunitinib in 
blocking the growth of breast cancer from responding to hormone stimulation. In this 
study, invasive mammary carcinoma was induced by using 70mg/kg body weight N-
Nitroso-N-Methylurea (NMU) in 32 young female Sprague Dawley rats. The gene 
and protein expressions of ER, PgR and HER2/neu markers were evaluated by using 
semi-quantitative immunohistochemistry analysis and quantitative real-time PCR 
assay. Findings from the untreated-control group demonstrated that all mammary 
lesions are 100% malignant, histopathological characterized with invasive breast 
carcinoma (IBC) of three major patterns; cribriform, papillary and no special type 
(NST). Sirolimus treatment showed significant inhibition of mammary tumour 
progression and downregulate the protein expressions of ER and PgR. However, high 
expressions of ER and PgR genes expressed on mRNA level might due to Sirolimus 
xx 
cause post-transcriptional regulation in gene. Meanwhile, tumour treated with 
Sunitinib reduced in diameter after first treatment, but the diameter increased after 
second treatment, and consequently showed no significant downregulation of ER and 
PgR. Histologically, Sunitinib treated tumour did not show any aggressive ductal 
NST histological subtypes. All NMU-induced tumours were HER2/neu-negative 
scoring. Tumour regression in combination treatment shown was predicted due to 
Sirolimus predominantly showed anticancer effect rather than Sunitinib. Thus, 











1.1 Background of the Study 
Breast cancer, commonly diagnosed cancer encountered in females which 
lead to mortality with various characteristics in clinical, pathological, and molecular 
(Bray et al., 2018). In Malaysia as reported in Malaysia National Cancer Registry 
Report (2019), breast cancer is the leading cause of female cancer death with 21,634 
cases of breast cancer reported on 2012-2016, accounted for 34.1% of all female 
cancer cases (Azizah et al., 2019). Hence, it is compulsory to conduct research to 
understand the pathogenesis of breast cancer and discover the targeted therapy for 
the detection and therapy of breast cancer.  
Estrogen hormone is important in normal mammary cell to regulate growth, 
differentiation and maintain homeostasis. Estrogen can cause cancer cells to develop 
by stimulating mammary tissue to mitosis; acts as a mitogen, and damaging DNA by  
acting as carcinogens (Cavalieri and Rogan, 2011). However, the effects of estrogen 
hormone alone do not fully lead for breast cancer development. Breast cancer 
tumours are dependent on estrogen and progesterone hormones binding to their own 
receptor. Human epidermal growth factor receptor-2 (HER2/neu) is a member of 
four homologous receptors family which actively involved in the tyrosine kinase 
mediated regulation, responsible for normal mammary tissue growth and 
development (Iqbal, 2014). The overexpression of HER2/neu in breast cancer 
associated with more tumour aggressiveness and poor prognosis. These three 
prognostic markers are routinely done in breast carcinoma screening. It not only 
helps in the prognosis of the tumour but also helps in deciding the best treatment. 
2 
In order to understand the biology of cancer and develop cancer prevention 
strategies, chemically induced carcinogenesis models in rat are widely used. There 
are several types of carcinogen used to induce cancer in animal model such as 9,10-
Dimethyl-1,2-benzanthrazen (DMBA), Diethylnitrosoamine (DEN), Azoxymethane 
(AOM), and N-Nitroso-N-Methylurea (NMU). NMU is a common inducer to 
establish rat mammary carcinoma models in human breast cancer study. NMU is 
administrated intraperitoneally (IP) to animals to induce the oncogenesis of the 
mammary ducts with high incidence of ER and PgR expressed in  mammary tumours 
(Alvarado et al., 2017). NMU-induced mammary carcinoma is age dependent; and 
the model is widely used to screen and evaluate the potency of cancer-suppressing 
and promoting agents. 
Sirolimus, also known as Rapamycin is isolated from bacterium Streptomyces 
hygroscopicus which initially developed as an antifungal agent until recently 
discovered with effective immunosuppressive and anti-proliferative characteristics 
by inhibiting mechanistic target of rapamycin (mTOR) (Li et al., 2014). Sirolimus is 
a mechanistic target of rapamycin inhibitor that has been shown to inhibit rather than 
promote cancers in experimental models. Sirolimus target mechanistic target of 
rapamycin complex 1 (mTORC1). Inhibition of mTORC1 will inhibit cell growth 
and proliferation by limiting nutrients, energy and oxygen status. However, long-
term exposure to Sirolimus will inhibits mechanistic target of rapamycin complex 2 
(mTORC2) by isolating newly synthesized mTOR molecules (Guduru and Arya, 
2017). 
Sunitinib (Sutent) is a tyrosine kinase inhibitor (TKI) indicated for first-
generation multi-targeted ATP-competitive TKIs including the vascular endothelial 
3 
growth factor receptors (VEGFRs) types 1 and 2 (FLT1 and FLK1/KDR), the 
platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), the Fms Related 
Receptor Tyrosine Kinase (FLT3), Rearranged during Transfection (RET) kinases, 
and the stem cell factor receptor c-Kit (Kaji and Yoshiji, 2017). The vascular 
endothelial growth factor (VEGF) family are frequently overexpressed in various 
solid tumours including mammary tumour and bind to vascular endothelium to 
induce angiogenesis. Inhibiting these tyrosine kinase receptors will block 
downstream signal transduction, thus inhibiting tumour growth and angiogenesis. 
Sunitinib antiangiogenic properties is use against treatment of gastrointestinal 
stromal tumor (GIST), renal cell carcinoma (RCC) (Adams and Leggas, 2007; Rizzo 
and Porta, 2017), adjuvant treatment of adult patients at high risk of recurrent RCC 
following nephrectomy (Fadil Hassan, 2018), and pancreatic neuroendocrine 
tumours (pNET) in patients with not resectable locally advanced or metastatic 
disease (Delbaldo et al., 2012), and approved by Food and Drug Administration 
(FDA) (Lopes and Bacchi, 2010).  
1.2 Problem Statement 
For decades, researchers all around the world have identified the important 
role of mTOR and tyrosine kinases in the breast cancer development and 
progression. In this study, the role of Sirolimus as anti-mTOR and Sunitinib as multi-
targeted tyrosine kinase inhibitor agents were used and analyzed towards retarding 
breast tumour growth. Sirolimus and Sunitinib were thought to downregulate the 
expressions of breast cancer prognostic markers such as ER, PgR, and HER2/neu. 
This can be a novel targeted therapy strategy to treat the specific molecular subtypes 
of breast cancer.  
4 
1.3 Objectives of the Study 
The general objective of the study is to investigate the expression of breast 
cancer prognostic markers (ER, PgR and HER2/neu) of NMU induced breast cancer 
under the influences of Sirolimus and/or Sunitinib in in vivo model.  
1.3.1 Specific Objectives 
The specific objectives of the study are:  
1. To investigate the morphological changes of NMU-induced breast cancer 
under the influence of Sirolimus and/ or Sunitinib. 
2. To analyze the effect of Sirolimus and/ or Sunitinib on molecular biomarkers  
of ER, PgR and HER2/neu of treated tumours using immunohistochemistry 







2.1 Overview on Breast Cancer 
2.1.1 Breast 
Breast is an organ from modified skin gland lies on the chest wall, sits atop 
the pectoralis muscle. Breast develops well in females as a vital accessory organ of 
the female reproductive system and rudimentarily develops in the males. The 
epithelial tissue of the breast contains lobules where milk is produce, and connects to 
ducts that lead out to the breast nipple. The major purpose of breast is to secrete milk 
for breastfeeding of the infants in a process called lactation, and also plays an 
essential role in female sexuality  (OpenStax, 2013). However, breast generally non-
functional form in males. Breast is divided into three parts; skin, parenchyma, and 
stroma (Pandya and Moore, 2011).  
The skin covering the breast is alike with the skin in another place on the 
body except at nipple and areola parts (Cimino-Mathews et al., 2020). The nipple 
contains circular and longitudinal smooth muscle fibres help in erecting the nipple 
upon stimulation, and is rich in the nerve supply. Areola is the dark pinkish-brown 
pigmented area around the nipple, rich in modified sebaceous glands that secrete oily 
secretion to prevent cracking of the nipple, and to provide lubrication for the nipple 
during nursing.  
Parenchyma is the glandular tissue of the breast made up of branching ducts 
and terminal secretory lobules. There are 15 to 20 lobes, and a lactiferous duct drains 
each of them. Each lobe is subdivided into many smaller lobules, separated by broad 
fibrous Cooper’s ligaments, which connect the skin with the fascia, or sheet of 
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connective tissue, that covers the pectoral muscles beneath the breast. Each lobe is 
drained by a separate excretory duct. These arborizing networks lobe is like a tree 
whose trunk, branches, and with hollow leaves to conduct mammary milk from the 
lobules to the nipple. The lobule consists of multiple blunt-ending ducts in a cluster 
like the fingers of a glove. These fingers form the glandular acini of the lobule. They 
are surrounded by specialized connective tissue called fascia. The acini and fascia 
together form the lobule. A terminal duct and its lobule are collectively called the 
terminal duct lobular unit (TDLU) (Figure. 2.1)(Pathology, 2020).  
  
  
Figure 2.1 Anatomy of the breast 
The female breast starts to develop and enlarge when reach puberty.  
Estrogen and progesterone stimulation involved in the development of the mammary 
glands and also associated in  proliferation of epithelial and connective tissue 
(Pandya and Moore, 2011). The structure of male breast is almost identical with the 
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female breast, except lacking of the specialized milk producing lobules, since male 
does not breastfeeding the baby. 
2.1.2 Breast Cancer Pathogenesis 
Cells within tissue normally communicate with each other using networks of 
locally produced chemicals such as hormones, growth factors and cytokines. These 
signals are crucial in numerous cellular homeostasis. Balance of proto-oncogenes and 
tumour suppressor genes are required for normal cell functions. However, mutations 
of these genes through insertions, deletions, or substitutions will resulting in gain or 
loss of functions, and will activate the signalling pathways which lead to 
tumorigenesis (Tuna and Amos, 2012).   
According Sever and Brugge (2015), cancer is determined by genetic and 
epigenetic alterations that allow cells to escape the normal cell cycle including cell 
proliferation and division, cell survival, cell death and apoptosis, cell differentiation 
and fate, cell motility and migration signalling pathway. The activating mutations of 
proto-oncogenes cause hyper activation of these signalling pathways, whereas 
inactivation of tumour suppressors reduces critical negative regulators of signalling 
(Sever and Brugge, 2015).  
For rationalizing the complexities of neoplastic disease, Fouad and Aanei 
(2017) have attempted to re-postulate previous seven hallmarks of cancer which are 
cell proliferation, altering stress response favouring overall survival including 
apoptosis and autophagy, inducing angiogenesis and vascularization, invading and 
metastasis, rewiring metabolic, abetting microenvironment, and modulating immune 
system (Fouad and Aanei, 2017).  
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Tumour are divided into two types; benign (not harmful to health) and 
malignant (very virulent or infectious) (Pietrangelo, 2019). The benign tumours or 
also called benign neoplasms are non-cancerous and only grow in one place. They 
are unable to spread or invade to other parts of the body (Kennecke et al., 2010; Liu 
et al., 2012). Differing from benign, malignant tumours are cancerous and can invade 
to other parts of the body (Yanhua et al., 2012). Benign tumour have potential in 
becoming  malignant tumour in woman who have family history which had altered 
genetic mutation (Zeinomar et al., 2019b). 
Breast cancer is a malignant tumour that has developed from cells in the 
breast. Breast cancer may develop in the cells of the lobules (lobular cancer), or the 
ducts (ductal cancer), or stromal tissues of the breast (Sharma et al., 2010). Breast 
tumour prognostic is based on degree of tubular formation, mitotic count, and 
nuclear pleomorphism (Rakha et al., 2010).  
Invasive breast carcinoma (IBC) of no special type (NST) pattern is the most 
commonly diagnosed breast cancer accounted for 75% of breast cancers (Sinn and 
Kreipe, 2013). IBC metastasize via lymphatics system from terminal duct lobular 
unit through the basement membrane of a breast duct with no specific histologic 
characteristics (Peter Abdelmessieh, 2018).  
2.1.3 Aetiology of Breast Carcinoma 
2.1.3(a) Gene mutation 
Gene and chromosome mutations are currently considered to be important 
end-points linked to heritable defects and to cancer stimulation. Generally, 5 to 10% 
emergence of this correspond cancer is due to inheritance of commonly mutated gene 
such as Breast Cancer Type 1 gene (BRCA1) or Breast Cancer Type 2 (BRCA2) 
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gene (Colditz et al., 2012). Statistically, a woman at 80 years old had 70% chance in 
developing breast cancer with the mutation of these two genes. Women with a 
BRCA1 mutation have a 55–65% lifetime risk of developing breast cancer 
statistically, while for women with a BRCA2 mutation, the lifetime risk is 45%. 
Women with one of these two mutations are also more likely to be diagnosed with 
breast cancer at a younger age, as well as to have cancer in both breasts. The impact 
of the BRCA1 and BRCA 2 mutation also associated with an increase of ovarian 
cancer risk as well (Petrucelli et al., 2010).  
Compared to BRCA mutations, there are less common and less drastic 
inherited mutations in other genes that also lead to increase of breast cancer risk. 
Some of the mutated genes involved in breast cancer development include Ataxia–
telangiectasia gene (ATM) (Jerzak et al., 2018), p53 gene (Kaur et al., 2018), 
Checkpoint kinase 2 (CHEK2) (Apostolou and Papasotiriou, 2017), phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) (Zhang et al., 2013), cadherine-1 
(CDH1) (Corso et al., 2018), PALB2 (Li et al., 2017), nibrin (NBN) gene (Uzunoglu 
et al., 2016), and Neurofibromatosis type 1 (NF1) genes (Salemis et al., 2010). 
Women with the high risk factor is  advisable for screening with precise genetic  
testing on these genes mutations (Lynch et al., 2015).  
2.1.3(b) Non-genetic aetiological factors 
Several aetiological factors that involved in the breast cancer pathogenesis 
comprises of late age, gender, family pedigree, food intake, alcohol consumption, 




Increasing age may increase aetiological risk of breast cancer. Breast cancer 
also associated in menopause women around 50 years (Kamińska et al., 2015). 
Additionally, according to epidemiological data, 50% of breast cancers occur in 
women aged from 50 to 69 years. Breast cancer is very uncommon before the age of 
20 years, but the incidence gradually increases with age, and by the age of 90 years, 
one-fifth of women are affected (Akram et al., 2017).  
Woman is highly risk of getting breast cancer due to sex hormones produced 
by the ovaries and the adrenal glands involved in the pathogenesis of breast cancer. 
Breast cancer is the most common cancer affecting women and accounts for 
approximately one quarter of all female cancers (Siegel et al., 2016), and only less 
than 1% of patients with breast cancer are males. The differences are thought to be 
due to sex hormonal factor. Increased percentage of positive Estrogen Receptor (ER) 
tumours diagnosed in women after menopause showed an interesting correlations 
between the age when this neoplastic disease is diagnosed (Ban and Godellas, 2014).  
Low in phytoestrogen diet, high intake of alcohol, obesity, and sedentary 
lifestyle increased the aetiology of breast cancer. Phytoestrogens diets have the 
ability to inhibit local estrogen synthesis, induce epigenetic changes, inhibit the 
transcriptional growth-promoting activity of ERα, and thus exert tumour growth 
inhibitory effects. Food with 35-40% of fat increased incidence of obesity which 
leading to breast cancer due to rich in cholesterol, source of steroid hormones 
production (Sieri et al., 2014). In addition, breast cancer risk increases with moderate 




2.1.4    Hormonal and growth receptors role in carcinogenesis of breast cancer 
These three aforementioned receptors are IHC markers that routinely 
performed in pathology laboratories, with well-established staining and evaluation 
protocols. These prognostic markers are responsible to mediate cell growth signalling 
and classically used for breast tumour subtyping (Park et al., 2012).  
2.1.4(a) Estrogen and Estrogen Receptor (ER) 
Estrogen hormone generally is a pace maker for female reproductive system 
and multi organ such as breast, bone, brain, and cardiovascular system. In breast, 
estrogen is vital in the normal breast epithelium development by promoting epithelial 
cell proliferation. Estrogen also act as pivotal mediators of ductal morphogenesis 
which occurs mostly postnatally under endocrine control (Brisken and O’Malley, 
2010). This ligand is a membrane‐soluble ligand which activates gene expression 
through intracellular receptors.  In premenopausal women, estrogen is synthesized 
primarily in the ovary (especially membrane granulose and luteinized granulosa 
cells), and in postmenopausal women, estrogen primarily synthesized in peripheral 
tissues. However, the proliferation and genetic instability induced by estrogen have 
been considered to increase transformation of normal cells into malignant cells 
through their expression of Estrogen Receptor (ER). 
Estrogen effects are mainly mediated through heptahelical receptor and 
binding to two nuclear ligand-activated transcription factors; ERα and ERβ. 
Estrogen-responsive elements bind to ERα and ERβ in the DNA to regulate the 
transcription of targeted genes.  Estrogen receptor is the key  in breast carcinogenesis 
and metastasis (Saha Roy and Vadlamudi, 2012b). Recent gene expression profiling 
(GEP) studies reported that ER status is the main predictor in breast cancer. ER 
positive tumours are mostly well-differentiated, attrite aggressive, and associated 
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with better recovery rate after surgery compared to ER-negative tumour. Powell et 
al. (2012) suggested that targeting both ER receptors offer better therapeutic 
management of breast cancer (Powell et al., 2012). 
These two transcriptional factors works by either initiate or suppress the 
expression level of related targeted genes such as ERα (NR3A1) and ERβ (NR3A2),  
encoded by two different genes called Esr1 and Esr2. Both  Esr1 and Esr2 have 
common structural features to uphold receptor-specific signal transduction through 
estrogen response elements (EREs) (Kulkoyluoglu and Madak-Erdogan, 2016).  
In the normal breast, ERα is found in luminal epithelial cells, whereas ERβ 
has been shown to be expressed in luminal, myoepithelial cells, and stromal cells 
(Brisken and Ataca, 2015). The major mediator of estrogen action is ER-α because it 
has a higher affinity to the physiological form of estrogen. ER-α is the main 
molecule associated with breast cancer development and progression.  Thus, the ER-
α expression status is widely used with other prognostic markers receptors in order to 
classify the breast cancer subtypes. 
Breast cancer cells have relatively high ERα expression and low ERβ 
expression (Huang et al., 2014). Upon formation of homo- or heterodimers, these 
complexes are translocating into the cell nucleus and regulate gene transcription. ER 
dimers bind to the estrogen response elements (EREs) region of targeted genes and 
convert co-regulators to achieve the regulation of transcriptional activity (Renoir et 




Figure 2.2 ER signalling pathway 
 
ERα in breast cancer tumorigenesis involved many factors and various 
occurrences of cross-talk (Saha Roy and Vadlamudi, 2012a). ERα promotes the 
breast tumour cell growth mainly characterized by mechanisms through interaction 
with cyclin D1. In cancer cells, cyclin D1 control the progression of cell cycle from 
G1 to S phase by activating cyclin-dependent kinases (CDKs) 4 and 6.  Mechanism 
of anti-estrogen therapy resistance also been  explained from the synergism within 
the ERα and cyclin D1 feedback loop, and suggesting the rationale for the combined 
use of selective CDK4 and 6 inhibitors with hormonal therapy in ER positive breast 




2.1.4(b) Progesterone and Progesterone Receptors (PgR) 
Progesterone is an ovarian hormone that soluble in membrane. Binding of 
progesterone to the intracellular receptors generate epithelial growth in the mammary 
gland (Macias and Hinck, 2012). Progesterone involved in alveologenesis and 
required for preparation for lactation‐competent gland formation during pregnancy.   
The progesterone signal is transmitted by the Progesterone Receptors (PgR), 
which encompasses of two isoforms; PgR-A and PgR-B that are only differentiated 
by 164 additional N‐terminal residues in PgR-B (Abdel-Hafiz and Horwitz, 2014). 
Imbalanced of PgR-A and PgR-B expression occurs early in carcinogenesis with 
predominance of one protein, usually PgR-A. However, the ratio of PgR-A:PgR-B 
imbalance in breast cancers is not associated with lifetime endogenous endocrine 
(Mote et al., 2015).  
There are diverse mechanisms that have different biological functions, but 
have been associated in the biological response to progesterone that may promote 
tumorigenesis such as RANKL, WNT4, and CyclinD1. Apart from that, progesterone 
also involved in RANK/RANKL signalling pathway. Upon binding with NFKB1 
ligand mediate the cell proliferation. Both RANKL and progesterone genes are co-
expressed in luminal epithelial cells during the morphogenesis of mammary lactation 
(Tanos et al., 2013).  
In luminal cells that expressed progesterone receptors (PgR), progesterone 
leads to the upregulation of RANKL expression. Recent studies demonstrating 
central role of RANKL in generating the pro‐growth response to progesterone to 
allow cell proliferation in progestin‐dependent breast cancers. In this regard, 
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progesterone has dual prominence works (Figure. 2.3) either by autocrine and 
paracrine.  
WNT signalling pathway is another downstream pathway that has been 
identified as oncogenic and may promote tumorigenesis in the mammary gland as 
reported by Tanos et al. (2013) using freshly isolated human breast tissue 
microstructures that found expression of both RANKL and WNT4 mRNA is induced 
by PgR signalling (Tanos et al., 2013).  
In short, progesterone binds its receptor in a subset of hormone receptor (HR) 
luminal cells or the sensor cells which is surrounded by myoepithelial or basal cells, 
which are in contact with the basal lamina. In certain PgR cells, it induces cell 
proliferation by a Cyclin D1-dependent mechanism (cell intrinsic signalling). It 
induces RANKL, which elicits cell proliferation in neighbouring HR cells (paracrine 
homotypic) and WNT4, which acts on myoepithelial cells (paracrine heterotypic) and 
increases stem cell activity (Figure 2.3) (Brisken et al., 2015) . 
 
Figure 2.3 Signalling downstream of progesterone.  
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The major downstream effector on estrogen action and act as the main ER 
target gene is PgR. Remarkably, there are broad cross-talk occurred between PgR 
with ER since both are required for mutual signal transduction pathways in 
mammary gland development and are most often elevated in breast cancer. For 
instance, the cross-talk between PgR-B and the tyrosine kinase growth factor 
receptors (Egfr) pathway.  Synergistic effect  between progesterone and EGF on 
numerous endogenous genes increase incidence of breast cancer carcinogenesis 
(Migliaccio et al., 2010). The functional significance of EGF-induced and PgR-B 
hyper activation along with ERα mediate proliferation of massive alveolar during 
mammary gland growth (Wu et al., 2015). 
2.1.4(c) HER2 signalling and HER2-Positive breast cancer 
Human epidermal growth factor receptor-2 (HER2/neu) or erythroblastic 
oncogene B 2 (c-ERBB2) one of the Epidermal Growth Factor (EGF) Receptor 
(EGFR) family among ErbB1/HER1, ErbB3/HER3, and ErbB4/HER4. HER2/neu 
may express in both normal and pathological tissues (Pines et al., 2010; Roskoski Jr, 
2014). HER2/neu is a proto-oncogene product from transmembrane tyrosine kinase 
growth receptor, thus involved in cancerous signalling pathway including 
proliferation, survival, cell motility, and invasion (Appert-Collin et al., 2015).  
HER2/neu positive breast cancers are more likely to metastasize, associated 
with inflammation and also expansion of cancer stem-like cells (CSCs) (Liu et al., 
2018b). A newly identified enhancer located at the 3′ gene body of HER2/neu was 




HER2/neu comprise of three multi-domains which are presence as 
extracellular, transmembrane, and intracellular domain (Arteaga and Engelman, 
2014). In the intracellular domain of HER2/neu, phosphorylation of tyrosine residues 
stimulated by binding of ligand and subsequent dimerization, affecting many cellular 
functions, which lead to the intracellular activation (Figure 2.4) (Feng et al., 2018). 
The downstream targeted pathways such as mitogen-activated protein kinase 
(MAPK) and the phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) pathways 
which are heavily associated with breast tumorigenesis (Mayer and Arteaga, 2016). 
HER2/neu as well as the others member of the EGFR family is located on the cell 
membrane and responds to a wide variety of ligands. Phosphorylation of the tyrosine 
kinase domain in the cytoplasm initiates downstream oncogenic signalling pathways 
such as PI3K/AKT pathway and Ras/MAPK pathway. 
Mammary tumour progression and proliferation is related with HER2/neu 
gene expression results in HER2/neu protein overexpression. A novel targeted 
treatment targeting to inhibit the signalling pathways that are important for cancer 
development and progression such as HER2/neu monoclonal antibodies are 
developed, and improved the prognoses of patients with positive HER2/neu breast 











2.1.5 Breast Cancer Classification 
Breast cancer demonstrated variety of biological and clinical behaviours. For 
several years, pathologists have recognized the biological and clinical heterogeneity 
of breast cancer. Understanding the morphology, molecular variation, histological 
structures and molecular pathological markers of breast cancer are used by 
pathologist in predicting clinical outcome and deciding appropriate treatment.  
IHC detection of estrogen receptor (ER), progesterone receptor (PgR), and 
HER2/neu are routinely been done for histopathological sub-classification of breast 
cancer, with or without additional cell proliferation markers such as Ki-67 (Ki-67). 
Positive hormone receptor of ER and PgR shows the tumour types targetable by 
hormone targeted therapy such as tamoxifen and aromatase inhibitors. Similarly, 
positive overexpression of HER2/neu can be treated with trastuzumab. Triple 
negative breast cancers (TNBC) referred to lack of ER, PgR and HER2/neu which 
are   not suggested for hormonal targeted therapies. TNBC are frequently associated 
with poor prognosis, exhibited a more aggressive behaviour, earlier and more 
frequent recurrence, and worse survival compared with positive prognostic breast 
cancer markers (Gonçalves et al., 2018).  
In order to classify the breast cancer subtypes, the ER, PgR and HER2/neu 
expression statuses have been considered as the most important features, where has 
been used in the dichotomized semi-quantitative immunohistochemistry evaluation. 
Breast cancer is classified into 5 molecular subtypes as summarized in Table 2.1 
(Guiu et al., 2012). 
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Table 2.1 Molecular subtypes of breast cancers 
Subtype Markers features Characteristics Treatment 
options 
Luminal A ER+, PR±, 
























Basal like ER-, PR-, 
HER2/neu - 
15-20%, worst 





Normal like ER+, PR±, 
HER2/neu -, Ki67 
low 
Rare, low proliferation 







2.1.6 mTOR signalling pathway and cancer 
The atypical phosphoinositide 3-kinase related kinase (PIKK) family 
mechanistic target of rapamycin (mTOR) is a member of the serine and threonine 
protein. mTOR is intracellular protein which is found downstream PI3K and protein 
AKT. mTOR signalling is critically important in regulating cell homeostasis and 
normal mammary development such as metabolism, protein and lipid production, 
cell survival, and organization of cell skeletal (Watanabe et al., 2011).  
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Due to mutations of mTOR, commonly mTOR is over active in multiple 
cancer types including breast cancer. However, besides mTOR mutation, increases in 
activity of HER family receptors or alterations and mutations of PI3K signalling also 
related to breast cancer incidence (Hare and Harvey, 2017). mTOR interacts with 
different proteins and comprises of two functionally different complexes, each 
defined by the specific co-factors in complex with mTOR kinase and by their relative 
sensitivity to rapamycin: mTORC1 and mTORC2 (Laplante and Sabatini, 2012).  
Both receptor-ligand complexes are involved in tumorigenesis through 
different mechanisms. mTORC1 is responsive to control several cellular processes, 
including protein and lipid synthesis, autophagy and lysosome biogenesis, nutrients, 
hormones, amino acids, hypoxia and growth factor signalling (Saxton and Sabatini, 
2017). Phosphoinositide 3-kinase/ Protein kinase B (PI3K/Akt) and Rat sarcoma - 
Mitogen activated protein kinase (Ras-MAPK) regulate mTORC1 signalling, and 
lead to activation of Signal transducer and activator of transcription (STAT3), 
Hypoxia-inducible factor 1α (HIF-1α), and Protein phosphatase 2A (PP2A) in 
tumorigenic (Figure 2.5)(Meng et al., 2018). mTORC1 requires the co-factor 
regulatory-associated protein of mTOR (Raptor), whereas mTORC2 requires the co-
factor rapamycin-insensitive companion of mTOR (Rictor) (Luo et al., 2015).  
mTORC2 plays role in cytoskeletal remodelling, responsible in ion 
transportation and cell cycle by regulating Serum glucose kinase (SGK) and Protein 
kinase C (PKC) (Ebner et al., 2017). However, IRS (insulin receptor substrate) 
indirectly regulates mTORC2 by mTORC1 via different feedback loops. mTORC1 
negatively regulates mTORC2 by two mechanisms. First, decrease the insulin 
signalling through phosphorylating insulin receptor substrate (IRS), and second 
inactivate of Akt through Akt phosphorylation and through the phosphorylation of 
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Rictor (Dalle Pezze et al., 2012). Akt is the main modulator for varies cellular 




Figure 2. 5 mTOR signalling pathway 
 
2.1.7 Angiogenesis in Breast Cancer 
Angiogenesis is referred to formation of new blood vessel which also 
involved in breast cancer initiation, progression, and malignancy (Paduch, 2016). 
Angiogenesis also involved in both local tumour growth and distant metastasis in 
breast cancer. A major pathway involved in angiogenesis is from hypoxic tumour 
cells release vascular endothelial growth factor (VEGF), and it is binding to the 
VEGF receptor (VEGFR), located on endothelial cells. Angiogenesis is cause by 
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transcription of pro-angiogenic genes within the nucleus of the endothelial cell, 
which was induced by activation of signalling cascade promoted by VEGFR (Ziyad 
and Iruela-Arispe, 2011).  
A ubiquitous feature of solid cancers is hypoxia. Hypoxia is a situation of 
incompatible between cellular oxygen supply and cellular oxygen consumption. 
Hypoxia able to stimulate the formation of neo-genesis (angiogenesis) and lymphatic 
vessels (lymphangiogenesis) to allow the cancer cells to escape the unfavourable 
tumour microenvironment and metastasis into secondary sites.  Thereby, hypoxia is 
highly associated with metastatic disease and mortality (Schito, 2019).  Lack of 
oxygen stimulates hypoxia-induced factor 1 alpha (HIF-1α), which then activates 
transcription of various proangiogenic cytokines such as VEGF (Schito and Rey, 
2017). In targeted genes including VEGF, the HIF-1 complex binds to hypoxia-
responsive elements in the promoter region which lead to over expression and 
contribute to angiogenesis. 
In breast cancer, the level of angiogenesis is associated with survival of 
tumour. VEGF is a major transcriptional target for HIF-1, thus is considered as vital 
factor playing a role in angiogenesis. The high levels of VEGF and other angiogenic 
factors indicate the high-risk disease with poor prognosis. In addition, VEGF also 
promotes vascular permeability, vasodilation, recruit endothelial progenitor cells 
from the bone marrow and inhibit apoptosis (Hoffmann et al., 2013). 
Recognition of the importance of angiogenesis for tumour growth and 
metastasis led researcher to lead advance research for therapeutic purpose by 
inhibiting this pathway (Wang et al., 2015). Since then, tyrosine kinase inhibitors 
targeting angiogenic factors such as VEGFR, platelet-derived growth factor receptor, 
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and others, were developed such as bevacizumab (anti VEGF-A), ramucirumab (anti-
VEGFR2) and Sunitinib (multi-targeted receptor tyrosine kinase).  
2.1.8 Prevalence of Breast Cancer  
Breast cancer is highly associated with female at advance age and lead to 
death (Desreux, 2018). Figure 2.6 shows the most common type of cancer incidence 
in 2018 worldwide. Breast cancer (presented in pink colour) showed the most 
incidence number and mortality rate among female globally. GLOBOCAN 2018 
reported that breast cancer (2,088,849 numbers of new cases) is the second common 
cancer diagnosed after lung cancer (2,093,876 numbers of new cases) on 2018 with a 
significant mortality at 626,679 number of death after lung cancer 1,761,007 (Bray et 
al., 2018).  
  
Figure 2. 6 Global Maps Presenting the Most Common Type of Cancer Incidence 
in 2018 in Each Country Among Women.  
